CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodkgina lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for targeted delivery of payloads by immunotherapeutics such as antibodies or engineered T-cells.
Monotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest efficacy results indicating the need for more effective payloads, but at the same time also providing development opportunities for new treatment modalities such as
This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment modalities. In B-cell non-Hodkgina lymphoma (NHL), CD22 expression ranges from 91% to 99% in the aggressive and indolent populations, respectively. CD22 expression occurs in more than 90% of patients with B-lineage acute lymphoblastic leukemia (ALL). CD22 is not expressed on non-B lineage cells or hematopoietic stem cells. In addition, CD22 is rapidly internalized after binding of the anti-CD22 antibody and is not shed in the extracellular environment, features that make it an attractive antigen for targeted delivery of payloads by immunotherapeutics such as antibodies or engineered T-cells.
Monotherapy of NHL and ALL with naked anti-CD22 antibodies only achieved modest efficacy results indicating the need for more effective payloads, but at the same time also providing development opportunities for new treatment modalities such as
- Combination therapies;
- Radioimmunotherapy (RIT);
- Immunotoxins (IT);
- Antibody-Dug Conjugates (ADC); and
- Chimeric Antigen Receptor (CAR) T-Cells.
- Target Background & Scientific Rationale
- Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
- Competitive Landscape
- Profiles of Anti-CD22 Immunotherapeutics
- Profiles of Companies with CD22-Targeted Immunotherapeutics.
Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics
Naked antibodies;
Radioimmunotherapy (RIT);
Immunotoxins (IT);
Antibody-Dug Conjugates (ADC); and
Chimeric Antigen Receptor (CAR) T-Cells.
Profiles of Companies with CD22-Targeted Immunotherapeutics.
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics
Naked antibodies;
Radioimmunotherapy (RIT);
Immunotoxins (IT);
Antibody-Dug Conjugates (ADC); and
Chimeric Antigen Receptor (CAR) T-Cells.
Profiles of Companies with CD22-Targeted Immunotherapeutics.
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics
